28-May-2019

Dr James Garner discusses ground-breaking Alliance study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media in Sydney to discuss Kazia’s participation in the ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.

08-May-2019

Dr James Garner discusses Kazia’s Phase 2 trial in glioblastoma with Proactive Investors

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the release of new safety and tolerability data from the company’s phase IIa trial of GDC-0084 in newly-diagnosed brain cancer patients.

08-May-2019

Kazia calls for greater awareness of one of the deadliest women’s cancers worldwide

This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of one of the deadliest women’s cancers worldwide.